...
机译:obinutuzumab与蕨类素司汀治疗卵泡淋巴瘤令人难以置疑的rituximab:证据审查集团的一个漂亮的单一技术评估的视角
Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR);
Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR);
Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR);
Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR);
Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR);
Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR);
Consultant in Haematology Barnsley Hospitals NHS Trust;
Consultant in Haematology Barnsley Hospitals NHS Trust;
机译:obinutuzumab与蕨类素司汀治疗卵泡淋巴瘤令人难以置疑的rituximab:证据审查集团的一个漂亮的单一技术评估的视角
机译:Pembrolizumab用于治疗复发或难治性古典霍奇金淋巴瘤:一份证据审查集团的一个漂亮的单一技术评估的视角
机译:与甲基摩甲段治疗的氯米二胺,用于治疗先前用Lenalidomide和Bortezomib治疗的复发和难治性多发性骨髓瘤:证据审查集团的观点,是一个漂亮的单一技术评估
机译:Brentuximab Vedotin治疗复发或难治性CD30-阳性皮肤T细胞淋巴瘤:一份证据审查集团的观点良好的单一技术评估
机译:Pembrolizumab用于治疗复发或难治性古典霍奇金淋巴瘤:一份证据审查小组视角是一个很好的单一技术评估